ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) CFO Dan Puckett sold 1,100 shares of ShockWave Medical stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $291.33, for a total transaction of $320,463.00. Following the completion of the transaction, the chief financial officer now directly owns 39,938 shares of the company's stock, valued at $11,635,137.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Dan Puckett also recently made the following trade(s):

• On Monday, August 22nd, Dan Puckett sold 1,100 shares of ShockWave Medical stock. The stock was sold at an average price of $292.21, for a total transaction of $321,431.00.
• On Wednesday, July 20th, Dan Puckett sold 1,350 shares of ShockWave Medical stock. The stock was sold at an average price of $207.09, for a total transaction of $279,571.50.

ShockWave Medical Stock Down 1.9 %

Shares of NASDAQ SWAV traded down $5.38 during trading hours on Wednesday, hitting $284.69. 442,971 shares of the stock were exchanged, compared to its average volume of 534,098. The company has a quick ratio of 4.41, a current ratio of 5.32 and a debt-to-equity ratio of 0.02. The company has a market cap of $10.19 billion, a PE ratio of 194.99 and a beta of 1.06. The firm has a fifty day moving average price of $262.48 and a 200-day moving average price of $207.86. ShockWave Medical, Inc. has a 12 month low of $113.36 and a 12 month high of $314.90.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. Wells Fargo & Company boosted their price objective on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a research report on Tuesday, August 9th. Morgan Stanley boosted their price objective on shares of ShockWave Medical from $201.00 to $255.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 9th. Piper Sandler boosted their price target on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an "overweight" rating in a report on Monday, August 29th. Finally, Oppenheimer lowered shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price target for the company. in a report on Tuesday, September 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $246.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in ShockWave Medical by 24.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,214,678 shares of the company's stock worth $614,550,000 after purchasing an additional 627,712 shares during the last quarter. State Street Corp grew its position in ShockWave Medical by 56.5% during the 2nd quarter. State Street Corp now owns 1,125,735 shares of the company's stock worth $215,207,000 after purchasing an additional 406,327 shares during the last quarter. Principal Financial Group Inc. grew its position in ShockWave Medical by 2,286.1% during the 2nd quarter. Principal Financial Group Inc. now owns 243,188 shares of the company's stock worth $46,490,000 after purchasing an additional 232,996 shares during the last quarter. Macquarie Group Ltd. grew its position in ShockWave Medical by 26.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,117,137 shares of the company's stock worth $213,563,000 after purchasing an additional 232,570 shares during the last quarter. Finally, Jennison Associates LLC grew its position in ShockWave Medical by 98.5% during the 1st quarter. Jennison Associates LLC now owns 433,534 shares of the company's stock worth $89,898,000 after purchasing an additional 215,142 shares during the last quarter. Institutional investors own 95.40% of the company's stock.

ShockWave Medical Company Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Recommended Stories

• Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
• General Mills: Superior Returns With Less Volatility
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• Is Ford Rolling To A Rebound After Its Q3 Warning

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.